Press release
Oncopeptides appoints Henrik Bergentoft as Chief Financial Officer
Stockholm – August 9, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.
“I am very happy that one of my first actions as CEO is to ask Henrik Bergentoft to join Oncopeptides, and I look forward to him taking on the role as CFO later this year,” says Sofia Heigis, CEO of Oncopeptides. “With his strong and varied background, I am sure that he will be a positive addition to our leadership team and I look forward to working closely with him to support the future growth of Oncopeptides.”